查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球免疫庫定序市場 - 產業分析、規模、份額、成長、趨勢、預測 (2031) - 按組件、按應用、按最終用戶、按地區
市場調查報告書
商品編碼
1389767

全球免疫庫定序市場 - 產業分析、規模、份額、成長、趨勢、預測 (2031) - 按組件、按應用、按最終用戶、按地區

Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 219 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

次世代定序 (NGS) 技術的最新進展為免疫組庫定序領域的突破性發現鋪平了道路。 這項尖端技術可偵測 B 細胞受體 (BCR) 和 T 細胞受體 (TCR) 的互補決定區域，正在徹底改變我們對人體抵禦外來病原體的防禦機制的理解。

免疫組庫定序可最大限度地減少侵入性和樣品需求，提供準確且靈敏的平台，並提供感興趣區域的動態視圖。 未來，該領域新方法的發展將發揮核心作用，特別是如果它們能夠提供比現有方法更全面的樣本見解。 免疫組庫定序的未來預計將由單細胞方法主導，該方法提供有關較小目標群體（包括抗原結合細胞）的高維度詳細資訊。

根據最近的預測，全球免疫組庫定序市場預計將以 7.3% 的複合年增長率成長，到 2026 年底將達到 1.73 億美元。 從價值來看，北美已成為主導的區域市場，預計亞太地區將出現強勁成長。

在北美，由於對抗癌症和傳染病的免疫療法的需求不斷增長，美國預計將引領市場。 正如美國國家癌症研究所所強調的那樣，免疫組庫定序方法的發展預計將在抗癌進展中發揮關鍵作用。

在醫療保健支出和政府資金不斷增長的推動下，歐洲是免疫庫測序的第二大區域市場。 該地區的競爭格局非常激烈，許多製造商為市場成長做出了貢獻。 此外，基因組定序價格的下降也刺激了對免疫組庫定序的需求。

亞太地區，尤其是中國和日本，全球免疫組庫定序市場正經歷顯著成長。 在國際合作和該地區技術進步的支持下，這項技術的採用正在增加。 拉丁美洲正在經歷先進產品引進和傳染病發病率上升推動的成長。

本報告考察了全球免疫譜庫定序市場，並提供了市場概述，包括按成分、應用、最終用戶、地區劃分的趨勢以及進入市場的公司的競爭趨勢。我是。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章 2018-2031 年全球免疫庫定序市場展望

  • 2018-2031 年全球免疫組庫定序市場前景（按組成部分、價值（百萬美元））
  • 2018-2031 年全球免疫組庫定序市場前景（按應用、價值（百萬美元））
  • 2018-2031 年全球免疫組庫定序市場前景（按最終用戶劃分）價值（百萬美元）
  • 2018-2031 年全球免疫譜定序市場前景（按地區、價值（百萬美元））

第 4 章 2018-2031 年北美免疫庫定序市場展望

第五章歐洲免疫譜定序市場展望，2018-2031

第 6 章 2018-2031 年亞太地區免疫庫定序市場展望

第 7 章拉丁美洲免疫庫定序市場展望，2018-2031

第 8 章中東與非洲免疫庫定序市場展望，2018-2031

第九章競爭態勢

  • 以最終使用者和使用情況劃分的熱圖
  • 按製造商和應用程式劃分的熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Illumina, Inc.
    • Pacific Biosciences of California, Inc
    • Agilent Technologies, Inc
    • Oxford Nanopore Technologies, Ltd
    • QIAGEN N.V.
    • Thermo Fisher Scientific
    • BGI
    • Takara Bio, Inc
    • F. Hoffmann-La Roche Ltd

第 10 章附錄

簡介目錄

Recent advancements in next-generation sequencing (NGS) technology have paved the way for groundbreaking discoveries in the field of immune repertoire sequencing. This cutting-edge technique, which probes the complementarity-determining regions of B-cell receptors (BCRs) and T-cell receptors (TCRs), is revolutionizing our understanding of the body's defense mechanisms against foreign agents.

Immune Repertoire Sequencing Unveils a World of Opportunities

Immune repertoire sequencing offers an accurate and sensitive platform with minimal invasiveness and sample requirement, providing a dynamic view of the region of interest. Looking ahead, the development of new methods in this field is poised to take center stage, particularly if they can offer more comprehensive sample insights compared to current techniques. The future of immune repertoire sequencing is expected to be dominated by single-cell approaches, offering high-dimensional and in-depth information on smaller populations of interest, including antigen-binding cells.

Market Projections and Regional Dominance

According to recent projections, the global immune repertoire sequencing market is set to grow at an impressive CAGR of 7.3% and is anticipated to reach a valuation of US$ 173.0 million by the end of 2026. In terms of value, North America is poised to emerge as the dominant regional market, with strong growth anticipated in Asia Pacific.

In North America, the United States is expected to lead the way due to a growing demand for immunotherapy in the fight against cancer and infectious diseases. Developments in immune repertoire sequencing methods are expected to play a pivotal role in the progress against cancer, as highlighted by the U.S. National Cancer Institute.

Europe is the second dominant regional market for immune repertoire sequencing, driven by increased healthcare expenditure and government funding. This region boasts a highly competitive landscape, with numerous manufacturers contributing to the market's growth. Additionally, price reductions in genome sequencing have spurred the demand for immune repertoire sequencing.

Asia-Pacific, specifically China and Japan, is witnessing significant growth in the global immune repertoire sequencing market. The adoption of this technology is on the rise, supported by international collaborations and technological advancements in the region. Latin America is experiencing growth fueled by advanced product introductions and the rising incidence of infectious diseases.

Conversely, the Middle East & Africa is expected to be the least attractive market due to challenges such as a lack of skilled personnel and limited internet access for data analysis. However, price reductions and international collaborations may spur future growth in this region.

Unlocking the Potential of Immune Repertoire Sequencing

High-throughput sequencing of immunoglobulin and TCR sequences is opening up numerous opportunities for advancing our knowledge of human biology and medicine. Immune repertoire sequencing holds immense promise in biomarker discovery, vaccine development, and transplant selectivity. However, it also comes with its share of challenges, including the need for new sequenced databases, computational algorithms, and advanced software for comprehensive data analysis.

In conclusion, the ever-evolving field of immune repertoire sequencing is poised for continuous growth, driven by scientific breakthroughs in TCR and BCR repertoire research. These developments will serve as the foundation for new clinical applications in personalized medicine, providing deeper insights into the behavior and response of adaptive immunity.

Table of Contents

1. Executive Summary

  • 1.1. Global Immune Repertoire Sequencing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 3.1. Global Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Assay Kits
        • 3.1.1.1.1. TCR Kits
        • 3.1.1.1.2. BCR Kits
      • 3.1.1.2. Software & Services
        • 3.1.1.2.1. Analytical Software
        • 3.1.1.2.2. Sequencing Services
        • 3.1.1.2.3. Data Analysis Services
  • 3.2. Global Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biomarker Discovery
      • 3.2.1.2. Infectious Diseases
      • 3.2.1.3. Vaccine Development and efficacy
      • 3.2.1.4. Cancer Immunotherapy
      • 3.2.1.5. Autoimmune Disease
      • 3.2.1.6. Transplant Rejection and Tolerance
      • 3.2.1.7. Others
  • 3.3. Global Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Academic Institutes
      • 3.3.1.2. Research Centres
  • 3.4. Global Immune Repertoire Sequencing Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 4.1. North America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Assay Kits
        • 4.1.1.1.1. TCR Kits
        • 4.1.1.1.2. BCR Kits
      • 4.1.1.2. Software & Services
        • 4.1.1.2.1. Analytical Software
        • 4.1.1.2.2. Sequencing Services
        • 4.1.1.2.3. Data Analysis Services
  • 4.2. North America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biomarker Discovery
      • 4.2.1.2. Infectious Diseases
      • 4.2.1.3. Vaccine Development and efficacy
      • 4.2.1.4. Cancer Immunotherapy
      • 4.2.1.5. Autoimmune Disease
      • 4.2.1.6. Transplant Rejection and Tolerance
      • 4.2.1.7. Others
  • 4.3. North America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Academic Institutes
      • 4.3.1.2. Research Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.2. U.S. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.3. U.S. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.4.1.4. Canada Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 4.4.1.5. Canada Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.6. Canada Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 5.1. Europe Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Assay Kits
        • 5.1.1.1.1. TCR Kits
        • 5.1.1.1.2. BCR Kits
      • 5.1.1.2. Software & Services
        • 5.1.1.2.1. Analytical Software
        • 5.1.1.2.2. Sequencing Services
        • 5.1.1.2.3. Data Analysis Services
  • 5.2. Europe Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biomarker Discovery
      • 5.2.1.2. Infectious Diseases
      • 5.2.1.3. Vaccine Development and efficacy
      • 5.2.1.4. Cancer Immunotherapy
      • 5.2.1.5. Autoimmune Disease
      • 5.2.1.6. Transplant Rejection and Tolerance
      • 5.2.1.7. Others
  • 5.3. Europe Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Academic Institutes
      • 5.3.1.2. Research Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.2. Germany Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.3. Germany Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.4. U.K. Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.5. U.K. Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.6. U.K. Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.7. France Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.8. France Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.9. France Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.10. Italy Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.11. Italy Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.12. Italy Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.13. Turkey Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.14. Turkey Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.15. Turkey Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.16. Russia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.17. Russia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.18. Russia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Assay Kits
        • 6.1.1.1.1. TCR Kits
        • 6.1.1.1.2. BCR Kits
      • 6.1.1.2. Software & Services
        • 6.1.1.2.1. Analytical Software
        • 6.1.1.2.2. Sequencing Services
        • 6.1.1.2.3. Data Analysis Services
  • 6.2. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biomarker Discovery
      • 6.2.1.2. Infectious Diseases
      • 6.2.1.3. Vaccine Development and efficacy
      • 6.2.1.4. Cancer Immunotherapy
      • 6.2.1.5. Autoimmune Disease
      • 6.2.1.6. Transplant Rejection and Tolerance
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Academic Institutes
      • 6.3.1.2. Research Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.2. China Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.3. China Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.4. Japan Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.5. Japan Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.6. Japan Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.7. South Korea Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.8. South Korea Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.9. South Korea Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.10. India Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.11. India Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.12. India Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 7.1. Latin America Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Assay Kits
        • 7.1.1.1.1. TCR Kits
        • 7.1.1.1.2. BCR Kits
      • 7.1.1.2. Software & Services
        • 7.1.1.2.1. Analytical Software
        • 7.1.1.2.2. Sequencing Services
        • 7.1.1.2.3. Data Analysis Services
  • 7.2. Latin America Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Biomarker Discovery
      • 7.2.1.2. Infectious Diseases
      • 7.2.1.3. Vaccine Development and efficacy
      • 7.2.1.4. Cancer Immunotherapy
      • 7.2.1.5. Autoimmune Disease
      • 7.2.1.6. Transplant Rejection and Tolerance
      • 7.2.1.7. Others
  • 7.3. Latin America Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Academic Institutes
      • 7.3.1.2. Research Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.2. Brazil Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.3. Brazil Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.4. Mexico Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.5. Mexico Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.6. Mexico Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.7. Argentina Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.8. Argentina Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.9. Argentina Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Immune Repertoire Sequencing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Component, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Assay Kits
        • 8.1.1.1.1. TCR Kits
        • 8.1.1.1.2. BCR Kits
      • 8.1.1.2. Software & Services
        • 8.1.1.2.1. Analytical Software
        • 8.1.1.2.2. Sequencing Services
        • 8.1.1.2.3. Data Analysis Services
  • 8.2. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biomarker Discovery
      • 8.2.1.2. Infectious Diseases
      • 8.2.1.3. Vaccine Development and efficacy
      • 8.2.1.4. Cancer Immunotherapy
      • 8.2.1.5. Autoimmune Disease
      • 8.2.1.6. Transplant Rejection and Tolerance
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Academic Institutes
      • 8.3.1.2. Research Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Immune Repertoire Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.2. GCC Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.3. GCC Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.4. South Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.5. South Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.6. South Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.7. Egypt Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.8. Egypt Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.9. Egypt Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.10. Nigeria Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.11. Nigeria Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.12. Nigeria Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Component, Value (US$ Mn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Immune Repertoire Sequencing Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Immune Repertoire Sequencing Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heat map
  • 9.2. Manufacturer vs by Application Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Illumina, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Pacific Biosciences of California, Inc
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Agilent Technologies, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Oxford Nanopore Technologies, Ltd
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. QIAGEN N.V.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Thermo Fisher Scientific
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. BGI
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Takara Bio, Inc
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations